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Brugada syndrome is an inherited cardiac arrhythmia that follows autosomal dominant
transmission and can cause sudden death. We report a case of Brugada syndrome in a 55-
year-old male patient presented with recurrent palpitation, atypical chest pain and pre-
syncope. ECG changes were consistent with type 1 Brugada. Gene analysis revealed a novel
missense mutation in SCN5A gene with a genetic variation of D785N and a nucleotide
change at 2353G-A. One of his children also had the same mutation. To our knowledge this
is the first genetically proved case of Brugada syndrome in Bangladesh.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Brugada syndrome is an inherited cardiac arrhythmia that
follows autosomal dominant mode of transmission. It can
cause syncope and sudden cardiac death in young individuals
with structurally normal heart due to rapid polymorphic
ventricular tachycardia (VT) or ventricular fibrillation (VF).
Brugada ECG is typically characterized by down sloping ST
segment elevation (coving type) in the right precordial
leads.1 These characteristics exhibit day-to-day variation
and may not always be present.2 Commonly the incidence
of arrhythmia occurs during resting period and often during
sleep.3 It has long been recognized as SUDS (sudden1, þ88 0171 8824627 (mob
m (Md.Z. Sayeed).
2013, Cardiological Socieunexplained death syndrome) in different regions of South-
east Asia.4
Brugada syndrome is genetically heterogeneous and is
linked to at least 8 different genes. Since its first diagnosis in
1992, a number of new genes linked to the disease and new
mutations are being consistently found. The commonest
mutation is in the SCN5A gene on chromosome 3, which en-
codes the pore-forming subunit of the cardiac voltage-gated
sodium channel.5 Although prevalent in Southeast Asia
there has been no case reported from Bangladesh.
The present case report is first of its kind where a new and
previously unpublishedmutation in SCN5A genewas detected
for Brugada syndrome.ile).
ty of India. All rights reserved.
Fig. 1 e (A and B): 12 lead initial ECG taken on 26/11/2011 showing type 1 Brugada pattern (A) and highlighted ST segment
elevation (coving type) in leads V1, V2 and V3 taken on 27/11/2011 (B).
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A 55-year-old male subsistence farmer was admitted in the
Cardiology unit of Rajshahi Medical College Hospital with
recurrent palpitation, atypical chest pain, dizzy feeling and
occasional presyncope that aggravated during last 1 year
especially on exposure to hot environment. He had no history
of night terror or agonal respiration. His initial ECG showed
down sloping ST segment elevation in V1, V2 and V3 leads
consistent with type 1 Brugada ECG (Fig. 1A and B). There is no
history of sudden death in his family. His physical examina-
tion was unremarkable and serial ECGs remained the same.
He was a heavy smoker but nondiabetic, normolipidaemic
with normal electrolyte and cardiac enzyme level. His chest
X-ray and echocardiogram were normal and coronary angio-
gram revealed normal coronaries. The patient was then pro-
visionally diagnosed as suffering from Brugada syndrome.
Genetic diagnosis was done at the Ramon Brugada Sr. foun-
dation, Cardiovascular Genetics Centre of Girona, Spain, that
revealed a novel missense mutation in SCN5A gene withinexon 15 of chromosome 3 with a genetic variation of D785N
and a nucleotide change at 2353G-A (Fig. 2). His eldest son
aged 39 years was mildly symptomatic with type III Brugada
ECG, had the samemutation, but nomutation was detected in
daughter’s sample.
Both father and the son were advised for regular follow up.
Avoidance of precipitating drugs, hot environment, emotion,
excitement and prompt use of antipyretic in fever was
stressed. Considering symptoms, ECG changes and genetic
test result ICD was indicated but patient could not afford it
due to high cost involved.3. Discussion
In 1992 Dr. Pedro and Joseph Brugada first described a new
clinical entity causing life-threatening ventricular tachyar-
rhythmia in patients with structurally normal heart which
later was named as Brugada syndrome.1,6 Although the dis-
ease is prevalent in Southeast Asia7 but to the best of our
Fig. 2 e DNA sequencing showing mutation in SCN5A gene within exon 15 of chromosome 3 with a genetic variation of
D785N and a nucleotide change at 2353G-A.
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Bangladesh. Our clinical suspicion of Brugada syndrome was
validated through genetic test from an authentic centre which
confirmed a new mutation in SCN5A gene. The same new
mutation was inherited by the proband’s eldest son (only two
of his five children agreed for gene testing) who was mildly
symptomatic.
To rule out the polymorphism a large database (exome
sequencing project) containing more than 10,000 alleles
(American and European controls) (http://evs.gs.washington.
edu/EVS/) was checked along with 1000 genome project
(http://browser.1000genomes.org/index.html) but no such
mutation was found in those controls. In Silico analysis
(computational analysis programs that predict the patho-
genesis of a variation) done in Girona, Spain, also ruled out the
prediction of a polymorphism. Functional analysis of the
mutation could be done, but it was not the usual protocol of
that centre and other centres as well due to the length of the
test. Expert opinion in this regard states that, if a variation has
been found it is generally assumed to be pathogenic since
controls worldwide do not have such variation. So by method
of exclusion, eventually this was considered a new mutation
of Brugada syndrome in our case.
Overall, 293 distinct possible BrS1-associated mutations in
SCN5A have been linked to the symptom in recent years.8Until now there have been mutations in 8 genes including
SCN5A that are known to cause Brugada syndrome.9
Considering the presence of new mutation in SCN5A gene
in our case, it can be well said that this is a case of Brugada
syndrome type 1. The proband has transmitted the mutation
to one of his offspring’s but lack of history of sudden death or
typical clinical features among his close relatives lead to the
sporadic nature of mutation in his case, although familial
forms are more common.10
Our patient presented with a clear type 1 Brugada ECG that
remained unchanged during follow up, so provocative test
with Ajmaline or Flecainide (sodium channel blocker) was not
considered. But it can be used as adjunct to substantiate the
clinical diagnosis of Brugada type 2 or type 3 ECG and dynamic
type 1 ECG.
In patients with Brugada syndrome and documented car-
diac arrest, ICD implantation is mandatory. In the remaining
patients, who constitute the vast majority of subjects
encountered in the clinical setting, the best policy is unclear.11
As our patient was symptomatic with type 1 Brugada ECG,
confirmed by genetic testing, ICD was indicated but due to
financial constraints of the patient it could not be given.
Further electrophysiology is usually done to substantiate
the clinical diagnosis and for risk stratification in Brugada.We
didn’t go for electrophysiology as patient declined ICD.
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newmutation in suspected cases but it is not widely available,
costly and moreover it cannot help in risk stratification. Thus
genetic testing is not routinely done for diagnosis of Brugada
syndrome.4. Conclusion
This is the first genetically proved case of Brugada syndrome
reported from Bangladesh. But considering its prevalence in
the neighboring countries, it is assumed that Brugada syn-
drome should have been prevalent here too. So diagnosis of
Brugada syndrome should be kept in consideration in patients
with suggestive symptoms or ECG changes.Conflicts of interest
All authors have none to declare.
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